1. Home
  2. GSBD vs COLL Comparison

GSBD vs COLL Comparison

Compare GSBD & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Goldman Sachs BDC Inc.

GSBD

Goldman Sachs BDC Inc.

N/A

Current Price

$7.69

Market Cap

943.9M

Sector

Finance

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

N/A

Current Price

$24.72

Market Cap

768.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GSBD
COLL
Founded
2012
2002
Country
United States
United States
Employees
N/A
423
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
943.9M
768.2M
IPO Year
2013
2015

Fundamental Metrics

Financial Performance
Metric
GSBD
COLL
Price
$7.69
$24.72
Analyst Decision
Sell
Buy
Analyst Count
5
8
Target Price
$8.63
★ $44.00
AVG Volume (30 Days)
★ 814.9K
533.8K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
★ 17.18%
N/A
EPS Growth
★ 87.27
N/A
EPS
0.05
★ 0.64
Revenue
N/A
★ $780,567,000.00
Revenue This Year
N/A
$6.59
Revenue Next Year
N/A
$1.89
P/E Ratio
$156.00
★ $39.44
Revenue Growth
N/A
N/A
52 Week Low
$7.70
$21.43
52 Week High
$10.38
$50.79

Technical Indicators

Market Signals
Indicator
GSBD
COLL
Relative Strength Index (RSI) 22.22 53.68
Support Level N/A $21.67
Resistance Level $9.08 $26.39
Average True Range (ATR) 0.22 0.92
MACD -0.08 0.05
Stochastic Oscillator 0.36 44.20

Price Performance

Historical Comparison
GSBD
COLL

About GSBD Goldman Sachs BDC Inc.

Goldman Sachs BDC Inc is a non-diversified, closed-end management investment company that elected to be regulated as a business development company focused on lending to middle-market companies. The investment objective is to generate current income and, to a lesser extent, capital appreciation through direct originations of secured debt, including the first lien, unitranche and second lien debt, and unsecured debt. It invests in U.S. middle-market companies such as banks and the public debt markets. The company focuses on the negotiation and structuring of the loans or securities in which it invests and holding the investments in its portfolio to maturity. It generates majority revenue in the form of interest income and dividend income.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: